<p>資本基金管理公司在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在 Tandem Diabetes Care, Inc.（NASDAQ:TNDM - 免費報告）股票的持有量提高了 575.4%。該基金在本季度額外購買了 223,574 股後，持有 262,431 股這家醫療設備公司的股票。截至最近的 SEC 文件，資本基金管理公司持有的 Tandem Diabetes Care 約佔 0.39%，價值 4,892,000 美元。</p>
<p>獲取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
<p>其他幾家對沖基金和機構投資者也調整了對 TNDM 的持有。拉塞爾投資集團在第二季度將其在 Tandem Diabetes Care 的股份提高了 42.9%。拉塞爾投資集團現在持有 198,713 股這家醫療設備公司的股票，價值 3,704,000 美元，此前在上個季度又購買了 59,619 股。顧問資產管理公司在第二季度將其在 Tandem Diabetes Care 的持有量增加了 11.3%。顧問資產管理公司現在持有 25,001 股這家醫療設備公司的股票，價值 466,000 美元，此前在該期間又購買了 2,541 股。XTX Topco Ltd 在第二季度獲得了 Tandem Diabetes Care 的新頭寸，價值約為 350,000 美元。愛德蒙·德·羅斯柴爾德控股公司在第二季度將其在 Tandem Diabetes Care 的股份提高了 4.0%。愛德蒙·德·羅斯柴爾德控股公司現在持有 262,600 股這家醫療設備公司的股票，價值 4,895,000 美元，此前在該期間又購買了 10,000 股。最後，Champlain Investment Partners LLC 在第二季度將其在 Tandem Diabetes Care 的持倉增加了 6.3%。Champlain Investment Partners LLC 現在持有 1,455,123 股這家醫療設備公司的股票，價值 27,123,000 美元，此前在上個季度又購買了 86,235 股。</p>
<h2>Tandem Diabetes Care 股票下跌 2.4%</h2>
<p>NASDAQ TNDM 的股票在週二開盤價為 20.51 美元。該股票的市值為 13.9 億美元，市盈率為-6.72，貝塔值為 1.68。該公司的 50 日移動平均線為 15.89 美元，200 日移動平均線為 16.06 美元。Tandem Diabetes Care, Inc.的 52 周低點為 9.98 美元，52 周高點為 38.28 美元。該公司的債務與股本比率為 2.33，速動比率為 1.90，流動比率為 2.44。</p>
<p>Tandem Diabetes Care（NASDAQ:TNDM - 獲取免費報告）最近在 11 月 6 日（星期四）發佈了其財報。這家醫療設備公司報告本季度每股收益為（$0.31），符合市場共識預期（$0.31）。該公司的季度收入為 2.4925 億美元，而分析師預期為 2.358 億美元。Tandem Diabetes Care 的淨利潤率為-20.19%，股本回報率為-73.97%。該公司的季度收入較去年同期增長了 2.2%。在去年同期，該公司每股收益為（$0.35）。Tandem Diabetes Care 已將其 2025 財年的指引設定為每股收益。整體而言，股票研究分析師預計 Tandem Diabetes Care, Inc.在當前財年將發佈每股收益-1.68 美元。</p>
<h2>分析師設定新目標價</h2>
<p>TNDM 最近成為幾份研究報告的主題。Weiss Ratings 在 10 月 8 日（星期三）的一份報告中重申了對 Tandem Diabetes Care 股票的 “賣出（e+）” 評級。富國銀行將 Tandem Diabetes Care 的目標價從 13.00 美元上調至 14.00 美元，並在 11 月 7 日（星期五）的研究報告中給予該公司 “持平” 評級。Canaccord Genuity Group 在 9 月 29 日（星期一）的研究報告中重申了對 Tandem Diabetes Care 的 “買入” 評級，並設定了 24.00 美元的目標價。華爾街 Zen 在 11 月 8 日（星期六）的報告中將 Tandem Diabetes Care 的評級從 “賣出” 上調至 “持有”。最後，Piper Sandler 在 8 月 7 日（星期四）的研究報告中將 Tandem Diabetes Care 的評級從 “增持” 下調至 “中性”，並將該公司的目標價從 30.00 美元下調至 14.00 美元。四位股票研究分析師對該股票給予了買入評級，十二位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Tandem Diabetes Care 目前的共識評級為 “持有”，共識目標價為 21.25 美元。</p>
<p><strong>獲取我們關於 TNDM 的最新研究報告</strong></p>
<h2>Tandem Diabetes Care 公司簡介</h2>
<p>（免費報告）</p>
<p>Tandem Diabetes Care, Inc.是一家醫療設備公司，設計、開發並商業化為生活在美國和國際上的糖尿病患者提供的技術解決方案。該公司的旗艦產品是 t:slim X2 胰島素輸送系統，這是一個用於管理胰島素輸送並直接在泵的主屏幕上顯示連續血糖監測傳感器信息的泵平台；以及 Tandem Mobi 胰島素泵，這是一個自動胰島素輸送系統。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Tandem Diabetes Care</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>2025 年上漲超過 20%，這三隻股票正在提升回購能力</li>
<li>什麼是道瓊斯狗策略？概述和示例</li>
<li>國會再次超越市場——這是他們購買的三隻股票</li>
<li>三隻提供優厚股息收益的天然氣股票</li>
<li>與三隻頂級零售 ETF 一起購物</li>
</ul>
<p><strong>想看看其他對沖基金持有的 TNDM 嗎？</strong> 訪問 HoldingsChannel.com，獲取 Tandem Diabetes Care, Inc.（NASDAQ:TNDM - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Tandem Diabetes Care 嗎？</h2>
<p>在考慮 Tandem Diabetes Care 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Tandem Diabetes Care 並不在名單上。</p>
<p>雖然 Tandem Diabetes Care 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TNDM

<p>資本基金管理公司（Capital Fund Management S.A.）在第二季度將其在 Tandem Diabetes Care, Inc.的持股增加了 575.4%，收購了 223,574 股。該基金目前擁有 262,431 股，價值 489 萬美元。其他機構投資者也調整了他們的持股。Tandem Diabetes Care 的股票開盤價為 20.51 美元，市值為 13.9 億美元。該公司報告第三季度每股收益為（0.31 美元），收入為 2.4925 億美元。分析師對該股票的評級不一，普遍評級為 “持有”，目標價為 21.25 美元</p>

<p>Capital Fund Management S.A. raised its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 575.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 262,431 shares of the medical device company's stock after buying an additional 223,574 shares during the quarter. Capital Fund Management S.A. owned about 0.39% of Tandem Diabetes Care worth $4,892,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>資本基金管理公司在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在 Tandem Diabetes Care, Inc.（NASDAQ:TNDM - 免費報告）股票的持有量提高了 575.4%。該基金在本季度額外購買了 223,574 股後，持有 262,431 股這家醫療設備公司的股票。截至最近的 SEC 文件，資本基金管理公司持有的 Tandem Diabetes Care 約佔 0.39%，價值 4,892,000 美元。</p>
</div><p>Get <strong>Tandem Diabetes Care</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
</div><p>Several other hedge funds and other institutional investors have also modified their holdings of TNDM. Russell Investments Group Ltd. raised its stake in Tandem Diabetes Care by 42.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 198,713 shares of the medical device company's stock valued at $3,704,000 after purchasing an additional 59,619 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in shares of Tandem Diabetes Care by 11.3% during the 2nd quarter. Advisors Asset Management Inc. now owns 25,001 shares of the medical device company's stock worth $466,000 after purchasing an additional 2,541 shares during the period. XTX Topco Ltd acquired a new position in shares of Tandem Diabetes Care during the second quarter valued at about $350,000. Edmond DE Rothschild Holding S.A. lifted its stake in shares of Tandem Diabetes Care by 4.0% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 262,600 shares of the medical device company's stock valued at $4,895,000 after buying an additional 10,000 shares during the period. Finally, Champlain Investment Partners LLC grew its position in Tandem Diabetes Care by 6.3% during the second quarter. Champlain Investment Partners LLC now owns 1,455,123 shares of the medical device company's stock worth $27,123,000 after buying an additional 86,235 shares in the last quarter.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者也調整了對 TNDM 的持有。拉塞爾投資集團在第二季度將其在 Tandem Diabetes Care 的股份提高了 42.9%。拉塞爾投資集團現在持有 198,713 股這家醫療設備公司的股票，價值 3,704,000 美元，此前在上個季度又購買了 59,619 股。顧問資產管理公司在第二季度將其在 Tandem Diabetes Care 的持有量增加了 11.3%。顧問資產管理公司現在持有 25,001 股這家醫療設備公司的股票，價值 466,000 美元，此前在該期間又購買了 2,541 股。XTX Topco Ltd 在第二季度獲得了 Tandem Diabetes Care 的新頭寸，價值約為 350,000 美元。愛德蒙·德·羅斯柴爾德控股公司在第二季度將其在 Tandem Diabetes Care 的股份提高了 4.0%。愛德蒙·德·羅斯柴爾德控股公司現在持有 262,600 股這家醫療設備公司的股票，價值 4,895,000 美元，此前在該期間又購買了 10,000 股。最後，Champlain Investment Partners LLC 在第二季度將其在 Tandem Diabetes Care 的持倉增加了 6.3%。Champlain Investment Partners LLC 現在持有 1,455,123 股這家醫療設備公司的股票，價值 27,123,000 美元，此前在上個季度又購買了 86,235 股。</p>
</div><h2>Tandem Diabetes Care Stock Down 2.4%</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 股票下跌 2.4%</h2>
</div><p>Shares of NASDAQ TNDM opened at $20.51 on Tuesday. The stock has a market cap of $1.39 billion, a PE ratio of -6.72 and a beta of 1.68. The business has a fifty day moving average of $15.89 and a two-hundred day moving average of $16.06. Tandem Diabetes Care, Inc. has a 52-week low of $9.98 and a 52-week high of $38.28. The company has a debt-to-equity ratio of 2.33, a quick ratio of 1.90 and a current ratio of 2.44.</p>
<div class="lb-trans"><p>NASDAQ TNDM 的股票在週二開盤價為 20.51 美元。該股票的市值為 13.9 億美元，市盈率為-6.72，貝塔值為 1.68。該公司的 50 日移動平均線為 15.89 美元，200 日移動平均線為 16.06 美元。Tandem Diabetes Care, Inc.的 52 周低點為 9.98 美元，52 周高點為 38.28 美元。該公司的債務與股本比率為 2.33，速動比率為 1.90，流動比率為 2.44。</p>
</div><p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its earnings results on Thursday, November 6th. The medical device company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). The business had revenue of $249.25 million for the quarter, compared to analyst estimates of $235.80 million. Tandem Diabetes Care had a negative net margin of 20.19% and a negative return on equity of 73.97%. The firm's quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.35) EPS. Tandem Diabetes Care has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Tandem Diabetes Care（NASDAQ:TNDM - 獲取免費報告）最近在 11 月 6 日（星期四）發佈了其財報。這家醫療設備公司報告本季度每股收益為（$0.31），符合市場共識預期（$0.31）。該公司的季度收入為 2.4925 億美元，而分析師預期為 2.358 億美元。Tandem Diabetes Care 的淨利潤率為-20.19%，股本回報率為-73.97%。該公司的季度收入較去年同期增長了 2.2%。在去年同期，該公司每股收益為（$0.35）。Tandem Diabetes Care 已將其 2025 財年的指引設定為每股收益。整體而言，股票研究分析師預計 Tandem Diabetes Care, Inc.在當前財年將發佈每股收益-1.68 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>TNDM has been the subject of several recent research reports. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Tandem Diabetes Care in a report on Wednesday, October 8th. Wells Fargo &amp; Company upped their target price on Tandem Diabetes Care from $13.00 to $14.00 and gave the company an &#34;equal weight&#34; rating in a research note on Friday, November 7th. Canaccord Genuity Group reaffirmed a &#34;buy&#34; rating and issued a $24.00 target price on shares of Tandem Diabetes Care in a research report on Monday, September 29th. Wall Street Zen raised shares of Tandem Diabetes Care from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. Finally, Piper Sandler cut shares of Tandem Diabetes Care from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and dropped their price objective for the company from $30.00 to $14.00 in a research note on Thursday, August 7th. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $21.25.</p>
<div class="lb-trans"><p>TNDM 最近成為幾份研究報告的主題。Weiss Ratings 在 10 月 8 日（星期三）的一份報告中重申了對 Tandem Diabetes Care 股票的 “賣出（e+）” 評級。富國銀行將 Tandem Diabetes Care 的目標價從 13.00 美元上調至 14.00 美元，並在 11 月 7 日（星期五）的研究報告中給予該公司 “持平” 評級。Canaccord Genuity Group 在 9 月 29 日（星期一）的研究報告中重申了對 Tandem Diabetes Care 的 “買入” 評級，並設定了 24.00 美元的目標價。華爾街 Zen 在 11 月 8 日（星期六）的報告中將 Tandem Diabetes Care 的評級從 “賣出” 上調至 “持有”。最後，Piper Sandler 在 8 月 7 日（星期四）的研究報告中將 Tandem Diabetes Care 的評級從 “增持” 下調至 “中性”，並將該公司的目標價從 30.00 美元下調至 14.00 美元。四位股票研究分析師對該股票給予了買入評級，十二位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Tandem Diabetes Care 目前的共識評級為 “持有”，共識目標價為 21.25 美元。</p>
</div><p><strong>Get Our Latest Research Report on TNDM</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 TNDM 的最新研究報告</strong></p>
</div><h2>Tandem Diabetes Care Profile</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc.是一家醫療設備公司，設計、開發並商業化為生活在美國和國際上的糖尿病患者提供的技術解決方案。該公司的旗艦產品是 t:slim X2 胰島素輸送系統，這是一個用於管理胰島素輸送並直接在泵的主屏幕上顯示連續血糖監測傳感器信息的泵平台；以及 Tandem Mobi 胰島素泵，這是一個自動胰島素輸送系統。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Tandem Diabetes Care</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>Congress Beat the Market Again—Here Are the 3 Stocks They Bought</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Go on a Shopping Spree With 3 Top Retail ETFs</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Tandem Diabetes Care</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>2025 年上漲超過 20%，這三隻股票正在提升回購能力</li>
<li>什麼是道瓊斯狗策略？概述和示例</li>
<li>國會再次超越市場——這是他們購買的三隻股票</li>
<li>三隻提供優厚股息收益的天然氣股票</li>
<li>與三隻頂級零售 ETF 一起購物</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TNDM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 TNDM 嗎？</strong> 訪問 HoldingsChannel.com，獲取 Tandem Diabetes Care, Inc.（NASDAQ:TNDM - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TNDM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tandem Diabetes Care Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Tandem Diabetes Care 嗎？</h2>
</div><p>Before you consider Tandem Diabetes Care, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Tandem Diabetes Care 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Tandem Diabetes Care 並不在名單上。</p>
</div><p>While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tandem Diabetes Care 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Capital Fund Management S.A. 收購了 Tandem Diabetes Care, Inc. 的 223,574 股股票，股票代碼為 $TNDM